MMB4 DMS

MMB4 DMS (1,1'-methylenebis-4-[(hydroxyimino)methyl]pyridinium dimethanesulfonate) is a next-generation bis-pyridinium oxime developed for the treatment of organophosphate nerve agent poisoning. It acts as an acetylcholinesterase reactivator and is designed to counteract the effects of nerve agents by restoring acetylcholinesterase activity at neuromuscular junctions and other nicotinic synapses. Compared to earlier oximes, MMB4 DMS offers improved chemical stability and broader efficacy against a range of organophosphates. However, it still faces challenges with hydrolytic degradation at elevated temperatures and limited blood-brain barrier penetration due to its hydrophilicity. Advanced formulations—including nanoparticle suspensions in biocompatible oils—have been developed to enhance its stability, shelf life, bioavailability, and rapid absorption for emergency use in autoinjector systems[1][2][5]. The U.S. Department of Defense has led development efforts for field deployment[7].

Other names

1,1'-methylenebis[4-[(hydroxyimino)methyl]-pyridinium] dimethanesulfonateMMB4 dimethanesulfonateMMB-4 dimethanesulfonateMMB 4 dimethanesulfonate